AUTHORS
Giuseppe Gaetano Loscocco, MD, PhD, Raffaella Santi2, Giada Rotunno, PhD3, Leonardo Signori, MSc4, Francesca Gesullo5, Valentina Boldrini6, Fabiana Pancani, PhD7, Chiara Maccari, MS8, Giulio Capecchi9, Paola Guglielmelli, MD, PhD10, Umberto Gianelli11, Alessandro Vannucchi, MD12
AFFILIATIONS
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Department of Health Sciences, Pathology Section, University of Florence, Florence, Italy
3 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
4 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
7 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
8 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
9 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
10 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
11 Pathology Unit, Department of Health Sciences (DISS), San Paolo Hospital, University of Milan, Milan, Italy
12 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
ABSTRACT
Background: Highly sensitive assays increasingly detect JAK2 V617F (JAK2) at very low variant allele frequency (VAF), posing a diagnostic challenge in patients presenting with MPN-like features. In unselected populations, low-VAF JAK2 may be interpreted as clonal hematopoiesis (CH); however, JAK2-mutant CH has been associated with higher blood counts and thrombotic/cardiovascular phenotypes, features overlapping with early-stage MPN.
Aim: To analyze clinicopathologic, molecular, and longitudinal correlates of low-burden JAK2 (VAF <2%) in 114 consecutive referral patients undergoing work-up for suspected MPN.
Methods: We included 114 consecutive patients referred to CRIMM, a tertiary MPN referral center at AOU Careggi, University of Florence, between 2010 and 2026, for suspected MPN who were found to harbor JAK2 VAF <2% during diagnostic work-up; clinically relevant reactive/secondary causes were excluded. JAK2 VAF was quantified in peripheral blood granulocyte DNA by ddPCR (limit of detection, 0.01%). Bone marrow (BM) biopsies were available in all patients and were centrally reviewed; final diagnoses were assigned by 2022 ICC/WHO criteria. Additional tests included CALR, MPL, JAK2 exon 12 when indicated, and cytogenetics. Myeloid NGS data were available in 55 patients; results for the remaining cases will be presented at the meeting.
Results: Median age was 62 years (18-92), 66% male. The median JAK2 VAF was 0.245% (range, 0.01-1.95). Referral phenotypes were erythrocytosis (n=43, 38%), thrombocytosis (n=51), and miscellaneous MPN-related features (n=20), including splenomegaly, atypical thrombosis, leukocytosis, or erythrocytosis with suspected systemic mastocytosis (SM). Prior or concomitant venous/arterial thrombosis occurred in 10%/11%, respectively. Among erythrocytosis cases, 9 fulfilled criteria for PV, whereas the remaining 34 were classified as MPN-U; they showed a PV-like BM phenotype, with age-adjusted normocellularity or focal hypercellularity, mildly expanded erythropoiesis, and scattered MPN-like megakaryocytes, although overall features were insufficient to meet PV criteria. Among thrombocytosis cases, final diagnoses were essential thrombocythemia (ET; n=36), prefibrotic primary myelofibrosis (pre-PMF; n=14), and overt PMF (n=1). The miscellaneous group included MPN-U (n=12), MDS/MPN-NOS (n=2), pre-PMF/overt PMF (n=4), MLN-TK with eosinophilia (n=1), and SM with associated myeloid neoplasm (n=1). Beyond low-burden JAK2, additional MPN driver lesions were identified in 37 patients: CALR in 26 and MPL in 11. Among thrombocytosis cases, 34/51 (67%) had concurrent CALR (n=25)/MPL (n=9) mutations, with median CALR/MPL VAF of 34%/20%. Taken together, these findings support a CALR/MPL-dominant pathobiology in thrombocytosis with concurrent low-burden JAK2. When compared with JAK2-only thrombocytosis, these patients were less often ET (56% vs 100%, p<0.001) and more often pre-PMF/overt PMF (44% vs 0%, p<0.001); they also had higher platelet counts (861 vs 546 ×10?/L, p<0.001), higher LDH (307 vs 221 U/L, p<0.001), and lower JAK2 VAF (0.165% vs 0.50%, p=0.019). Among 55 patients overall with NGS data, additional myeloid mutations were found in 25 (45%): ASXL1 (13%), SF3B1 (9%), TET2 (7%), and DNMT3A, KIT, SH2B3 and NF1 (5% each) were the most frequent; myeloid mutations were enriched in miscellaneous presentations (75% vs 35% in erythrocytosis and 31% in thrombocytosis; p=0.018). Abnormal karyotype was detected in 10/110 evaluable patients, without phenotype-specific enrichment. Serial JAK2 VAF assessment was available in 29 patients over a median follow-up of 2 years (range, 0.6-6.2). JAK2 VAF remained <2% in 25/29 (86%); the 4 cases exceeding 2% had near-threshold baseline VAFs (1.9-1.95%) and reached a median VAF of 3.5% (range, 3-10.5%) after a median of 2 years.
Conclusions: In patients referred for an MPN-like phenotype, the clinical significance of low-burden JAK2 VAF (<2%) is context-dependent and should be defined by integrating clinical phenotype, hematologic features, BM morphology, molecular findings, and clonal dynamics. In thrombocytosis, low JAK2 VAF was associated with CALR/MPL mutations in two-thirds of cases, supporting cascade driver testing. Incidental JAK2-associated CH should be considered only in cases lacking sufficient supportive clinicopathologic evidence.
DISCLOSURES
Giuseppe Gaetano Loscocco, MD, PhD: AOP Health - Honoraria; AOP, GSK, Novartis - Honoraria; Novartis - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony)